Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Intranasal Immunization with Mumps Virus DNA Vaccine Delivered by Influenza Virosomes Elicits Mucosal and Systemic Immunity
Author links open overlay panel Maria GraziaCusia1 Rinaldo Zurbriggen bMarcelloValassinaaSilviaBianchiaPeterDurrerbPier EgistoValensinaMarcoDonatia Reinhard Glückb
a
Department of Molecular Biology, Section of Microbiology, University of Siena, Via Laterina 8, Siena, 53100, Italy
b
Department of Virology, Swiss Serum and Vaccine Institute, Berne, Switzerland
These results suggest that cationic virosomes in combination with Escheriagen may have great potential as an efficient delivery system for intranasal DNA immunization and provide an immune barrier at the mucosal sites.
https://www.sciencedirect.com/science/article/pii/S0042682200906056?via%3Dihub
Welcome to the website of the Eggel Lab! Our research group is affiliated with the Department for BioMedical Research (DBMR) at the University of Bern and the Department of RIA at the University Hospital Bern in Switzerland. Our major research interests focus on the biologic mechanisms underlying both beneficial as well as pathogenic type 2 immune responses. On the one hand we are trying to get a better understanding on how allergies evolve and to develop alternative treatment approaches directly interfering with the allergic cascade. On the other hand we are investigating the development of age-related disorders and how they are linked to alterations in type 2 immune responses. In our studies we integrate molecular, cellular and systemic approaches to identify important biological mechanisms involved in the pathophysiology of a disease.
University of Bern
http://eggellab.com/index.php
http://eggellab.com/index.php/team/dr-alexander-eggel
Allergy
. 2021 Mar;76(3):853-865. doi: 10.1111/all.14608. Epub 2020 Nov 13.
Accuracy of serological testing for SARS-CoV-2 antibodies: First results of a large mixed-method evaluation study
recombinant receptor-binding domain (RBD) of the SARS-CoV-2
Daniel Brigger 1 2, Michael P Horn 3, Luke F Pennington 4, Abigail E Powell 5 6, Denise Siegrist 7, Benjamin Weber 7, Olivier Engler 7, Vanja Piezzi 8, Lauro Damonti 8, Patricia Iseli 9, Christoph Hauser 8, Tanja K Froehlich 3, Peter M Villiger 1, Martin F Bachmann 1 2, Stephen L Leib 10, Pascal Bittel 10, Martin Fiedler 3, Carlo R Largiadèr 3, Jonas Marschall 8, Hanspeter Stalder 11, Peter S Kim 5 6, Theodore S Jardetzky 4, Alexander Eggel 1 2, Michael Nagler 3
https://pubmed.ncbi.nlm.nih.gov/32997812/
Natural Killer Cells Can Be “Reprogrammed”
TOPICS: Cancer Immune System University Of Bern
By UNIVERSITY OF BERN NOVEMBER 19, 2019
Killer cells of the immune system detect and kill infected cells or cancer cells. Researchers at the Institute of Pathology at the University of Bern have now discovered that the mechanism by which certain immune cells kill their target cells can also be used to control the killer cells themselves. This finding may be relevant to cancer immunotherapy.
https://scitechdaily.com/natural-killer-cells-can-be-reprogrammed/
Hope they use VIROSOMES for the Delivery!!
It WORKS!! SEND IT :)
Susan Walton - Director, Merck Global Finance - Lean Six ...
www.linkedin.com › in › susan-walton-3b91757
Director, Merck Global Finance - Lean Six Sigma Master Black Belt for Finance Merck. ... Chief Executive at Pestalozzi International Village Trust. Tonbridge, United Kingdom.
https://www.linkedin.com/in/susan-walton-3b91757/
Kenneth Greatbatch
Board Chair, PestalozziWorld UK
Ken, a Chartered Accountant, is Chairman of Global 365 plc. His career in developing public, private equity and family businesses culminated in the founding of AZ Electronic Materials Plc, which was publicly traded before being acquired by Merck.
https://www.pestalozziworld.com/our-people
Unitectra: Technology Transfer Universities of Basel, Bern and Zurich
BOARD OF DIRECTORS
Markus Hosang, Dr., Chairman; General Partner, BioMedPartners, Basel
https://www.unitectra.ch/en/about-unitectra/board-of-directors
The main services of Unitectra include:
Commercialization of research results: protection and management of intellectual property (patents, copyright, trademarks, etc.), commercialization strategy, search for suitable commercial partners, negotiation of licensing agreements
https://www.unitectra.ch/en/about-unitectra
The aim of the DBMR is to build bridges between laboratory-based and patient-oriented clinical research. It also focuses on the development of translational research and the application of so-called Omics methods.
Ronald Kempers, CEO of Mymetics SA, is looking forward to working with the specialists of the DBMR and the University Hospital Bern: "This cooperation, supported by Innosuisse, is a very good example of our strategy: With targeted cooperation, we bring specific expertise to our projects." Prof. Geiser adds: "The pressure for success in Covid-19 vaccine research is enormous. We are pleased that, with the University Hospital and the University of Bern, we can contribute to generating results at a solid scientific level, from which the entire population can hopefully benefit soon."
https://www.unibe.ch/aktuell/medien/media_relations/medienmitteilungen/2020/medienmitteilungen_2020/insel_gruppe_erhaelt_zuschlag_fuer_covid_19_impfforschung/index_ger.html
The DBMR aims to bridge laboratory-based biomedical
and patient-oriented clinical research through the scientific support of its groups and by operating state-of-the-art
Technology Core Facilities and specialized Animal Core
Facilities. In addition, a strong emphasis is put on the development of translational approaches and the use of omics
technologies
https://www.dbmr.unibe.ch/e40513/e483390/e633636/files848163/DBMR_AR2018_WEB_eng.pdf
Our strategy is to support clinical research in an integrative manner bridging laboratory-based and patient-oriented clinical research. In addition, we put a strong emphasis on the development of translational approaches and the use of omics technologies. We are convinced that these will revolutionize the field of clinical research.
Carine Van Den Brink
University of Groningen
Degree Name MSc Field Of Study medicine
Dates attended or expected graduation1982 – 1987
https://www.linkedin.com/in/carine180664/?originalSubdomain=nl
I like that Trivia!! Toon getting ready for Retirement? Very Nice Friend!! :)
Toon Stegmann
© Toon Stegmann
Toon Stegmann (1959) has been a councillor since 2018 and also chairman of the VVD Katwijk. Toon lives in Rijnsburg.
https://katwijk.vvd.nl/mensen/7644/toon-stegmann
https://www.linkedin.com/in/toon-stegmann-637b305/?originalSubdomain=nl
What they own is what we own!! :)
Paul G. Allen launched the Allen Institute for AI (Bill Gates) Microsoft!
nice picture of Lake Washington and 99 Bridge!!
https://allenai.org/?utm_campaign=CORD-19&utm_source=hs_email&utm_medium=email&utm_content=2&_hsenc=p2ANqtz-_gW0dPpH2hRGYmrg_1CQFlULUuvgSgDZtsc0yvfnuR4nlk8_1iEWcrR-YmaGoeS30LwfZxjEh8PPndW45-dWj_vutI3A&_hsmi=2
My friend it's the Major share holders holding this back and they are common holders like us. Mymetics will not screw there big thunders. I would not! Might be there lives!! :) Millionaire's Billionaire's I would not screw them if you know what I mean!!
Not if they buy it my friend!! ;)
So what if newer variant's pop up, There going to tackle each one with a Booster shot! LMAO!! WE NEED THE UNIVERSAL COVID VACCINE!! PERIOD :)
Puddles Pity Party Sounds Of Silence
For you Mr. Kemper's sound of silence!!!!!!!!!!
Bring the SOUND!!!!!!!!!!! MR. KEMPER'S
from last post!!
Establishment of in vivo lung function measurements with FlexiVent (Scireq) device
https://www.scireq.com/flexivent/
https://www.scireq.com/applications/
Céline Ferrié – Research associate – Department biomedical ...
ch.linkedin.com › in › céline-ferrié-a83b1316
Production of specific virosome with hemagglutinin and ovalbumin on the surface ... Journal of heart and lung transplantation (2013). ... , Organs-on-Chip Group
Location: Bern, Bern, Schweiz
Céline (Giroud) Ferrié
Biology research associate, MSc
Bern, Berne, Switzerland
Research associate
Company Name Department biomedical research, pneumology laboratory
Dates Employed Apr 2017 – Present
Employment Duration4 yrs
Location Région de Berne, Suisse
Projects:
? Production of specific virosome with hemagglutinin and ovalbumin on the surface
? Development of protocols to determine the efficiency of virosome against asthma consequences in mouse model
? Establishment of in vivo lung function measurements with FlexiVent (Scireq) device
https://www.linkedin.com/in/c%C3%A9line-ferri%C3%A9-a83b1316/?originalSubdomain=ch
See has a Mario White paper on her linkedin page
https://media-exp1.licdn.com/dms/document/C4D2DAQE17Tu7aO3FKg/profile-treasury-document-pdf-analyzed/0/1583449221189?e=1615399200&v=beta&t=waJRoyk0ixd1UhAzUi-WUxVIr6jiY6mTwqoKjfltHUI
3 BRILLIANT MINUTES: Lung on a Chip
www.wbay.com › 02 › 23
Feb 23, 2021 · 3 BRILLIANT MINUTES: Lung on a Chip. Published: Feb. 23, 2021 at 5:20 PM CST. News. Kimberly loses in D1 State Championship. Updated: 7 hours ago. Kimberly lost 62-44 in the WIAA Division 1 State ...
https://www.wbay.com/video/2021/02/23/brilliant-minutes-lung-chip/
(PDF) Membrane Fusion Mediated Targeted Cytosolic Drug ...
www.researchgate.net › publication › 275894907
Hence, this immuno-virosome, which is devoid of the comparatively more toxic HN protein, has the ... was observed by ChIP assay, which decreased upon trichostatin A treatment, indicating a ..
Abstract:
Antibody targeted cytoplasmic delivery of drugs is difficult to achieve as antigen-antibody interaction results in the payload being directed to the endosomal compartment. However, Sendai viral envelopes can bring about cytoplasmic delivery due to F-protein mediated membrane fusion. In this study we have generated and fused a recombinant scFv directed to the onco-fetal antigen, the Placental isozyme of Alkaline Phosphatase (PAP) with the trans-membrane and part of the cytoplasmic domain of the Sendai F protein (FTMC). Reconstituted virosomes, having both the fusion protein as well as the native F-protein were able to specifically bind and deliver drugs to PAP expressing cells. About 75% of the delivery was cytoplasmic in nature. Hence, this immuno-virosome, which is devoid of the comparatively more toxic HN protein, has the novel ability to combine specific antibody mediated targeting with cytoplasmic delivery. The scFv ensured specific binding to PAP expressing cells, without cross reacting with the other isozymes of alkaline phosphatase. The advantages of cytoplasmic delivery would include reduced degradation and lowered immunogenicity of the payload and carrier. The ubiquitous expression of PAP on a variety of cancers like seminoma, choriocarcinoma, cervical and breast cancers also suggests its potential usefulness in a number of malignancies.
This says that VIROSOMES BIG DEAL IN CANCER DRUG DELIVERY!! LOOKS LIKE
A CHIP WAS USED!!
Keywords: F-protein, F-virosome, placental alkaline phosphatase, scFv, Sendai virosome, targeted drug delivery.
https://www.eurekaselect.com/130995/article
Another Small video shows infections on lung on a chip!! :)
https://www.artorg.unibe.ch/unibe/portal/fak_medizin/dept_weitere/ins_artorg/content/e977173/e977176/e977251/e993992/index_eng.html
https://www.eurooc.eu/7-project/
Thank-You for all you do to my friend! Stay safe you and yours :) Thanks for the great DD's!! Keep it coming ;) Later Bro!!
Stem Cells:
Articles by Mario Amacker
Between 2010 and 2021, Mario Amacker wrote the following eligible article about Stem Cells:
ABSTRACT: Our understanding of mesenchymal cell subsets and their function in human lung affected by aging and in certain disease settings remains poorly described. We use a combination of flow cytometry, prospective cell-sorting strategies, confocal imaging, and modeling of microvessel formation using advanced microfluidic chip technology to characterize mesenchymal cell subtypes in human postnatal and adult lung. Tissue was obtained from patients undergoing elective surgery for congenital pulmonary airway malformations (CPAM) and other airway abnormalities including chronic obstructive pulmonary disease (COPD). In microscopically normal postnatal human lung, there was a fivefold higher mesenchymal compared with epithelial (EpCAM
https://www.expertscape.com/ar/stem+cells/a/Amacker%2C+Mario
Sylvain Fleury
Chief Scientific Officer at Mymetics Corporation
Post-doctoral fellowship
Company Name NIH
Dates Employed Jan 1993 – Dec 1996
Employment Duration4 yrs
Studying the MHC classe II and CD4 structure-function in the context of antigen presentation. Fellowship with Dr. Ronald N. Germain from the NIAID (Bethesda, Maryland, USA).
Ronald Germain, M.D., Ph.D.
https://www.niaid.nih.gov/research/ronald-n-germain-md-phd
Stegmann said, 'We make vaccines based on virosomes, very small particles. They can be suitable for fighting the coronavirus, because they generate a good immune response.'
https://fd.nl/achtergrond/1349520/het-coronavaccin-komt-misschien-wel-uit-nederland
I know where that is my Friend! Been there in that Industrial Park! :)
Dynamism in medical research
Several organisations and research institutions have already taken advantage of the opportunity and launched various projects. In the medical world, the Vaud-based biotech company Mymetics is currently developing a unique vaccine in collaboration with the University Hospital of Bern. The team is conducting research to create a prophylactic nasal vaccine. Most of the Covid-19 vaccines currently under development or being deployed in vaccination campaigns are administered by intramuscular injection to induce immune defense responses in the blood. According to the scientific teams, however, there is no or only very limited protection in the nasal area, although this is the main point of entry and replication site for the virus. This vaccine will induce immune protection not only in the blood but will also elicit immune defense protection in the nasal and pulmonary mucous membranes and therefore aims to prevent transmission of the virus and infection at a very early stage before it spreads to other organs. Other teams are aiming to improve vaccine efficacy and long-term immunity.
https://www.innosuisse.ch/inno/en/home/funding-business-information/covid-19-innovation/innovation-projects.html
Yes, Not only Covid, MYMX has Allergy, HIV, Malaria, Influenza, Oncology. :) Majority of Longs know my friend! Your one of them! :)
Maybe that is why CDC was at Bern door steps!!
Bern coronavirus clone goes "viral"
https://www.unibe.ch/news/media_news/media_relations_e/media_releases/2020/media_releases_2020/bern_coronavirus_clone_goes_viral/index_eng.html
Yep! Volker Thiel is on top of all Variant!! That's why universal my friend!! :)
looks like mymetics might have the answer my friend! :)
From Last Post:
ovalbumin Virosomes: only ovalbumin-coupled virosomes generated a strong antigen-specific CD4+ T cell proliferation. Pulmonary administrated antigen-coupled virosomes therefore effectively induced adaptive immune responses and may be utilized in novel preventive or therapeutic approaches in the respiratory tract.
https://pubmed.ncbi.nlm.nih.gov/28439267/
FEBRUARY 26, 2021
SARS-CoV-2 mutations in competition
by University of Bern
The D614G variant carries a mutation in the spike protein that makes it easier for the virus to dock onto human cells. The researchers at IVI and in David E. Wentworth's laboratory at the Centers for Disease Control and Prevention in Atlanta (USA) first demonstrated in human cell cultures from the upper respiratory tract, as well as from the nose, that the D614G variant binds more strongly and also replicates faster than the original virus. The increased replication of the D614G variant was also confirmed in vivo, in a new mouse model first described in this study. These experiments were also carried out at the IVI in Charaf Benarafa's group.
Our testing strategy allows us to rapidly examine why other, newly emerging virus variants have become established," says Volker Thiel.
Similar research projects on infectious pathogens could also be carried out in the future at the newly established Multidisciplinary Center for Infectious Diseases and Immunity (MCIDI) at the University of Bern.
So if Bern can see all variants in the in the virus, That means that a universal vaccine can be applied!! IMO!! :) and it works!!
Yes, Dr Beltrami also wanted to get back to Merck-Serono some day!! :)
A Study of the Effects of Single Dose Corticosteroids on ...
inclinicaltrials.com › allergic-rhinitis › NCT00828061
NCT02943720 - ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen Phase 2: Completed NCT02556801 - Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy Phase 2: Completed NCT02352168 - Airway Inflammation in Children With Allergic Rhinitis and Intervention N/A: Not yet recruiting
https://inclinicaltrials.com/allergic-rhinitis/NCT00828061/
Nice!! ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
STATUS
Not Recruiting
PARTICIPANTS NEEDED
400
SPONSOR
Anergis
Updated on 22 January 2021
https://www.centerwatch.com/clinical-trials/listings/104518/allergic-rhinitis-atibar--efficacy-safety/
From Last Post:
Dr. Beltrami brings over 20 years of experience in the pharmaceutical industry with Ares-Serono, Laboratoires Serono SA and Merck Serono SA, where he held several positions with direct product development responsibility (e.g. somatropin), acting as final dosage forms project director and manufacturing product director. Most recently, he was Global Product Team Leader at the Global Product Unit Endocrinology, where he substantially expanded his cross-functional pharmaceutical development experience.
Dr. Beltrami has a long-standing track record in drug product and medical devices development as well as drug launches in multiple countries. His expertise also includes the life cycle management of a brand product generating € 250 M sales per year. Vanya Beltrami was trained as a pharmacist and holds a PhD in Formulation from the University of Geneva.
https://www.akampion.com/news/2014/06/company-news-anergis-appoints-dr-vanya-beltrami-as-director-product-development/
Vanya Beltrami What's he up to?
Geneva Area, Switzerland
Sr Program Director Endocrinology at Merck Serono International SA
Outsourcing/Offshoring
https://graduates.name/country-ch-1336#: Graduates In Switzerland
Outsourcing/Offshoring
https://fullscale.io/blog/offshoring-vs-outsourcing-difference/
Right! Martin Bachmann and Sarah Gilbert ChAd63-ovalbumin (OVA)2021
You have White Eggs on your FACE!!
Vaccines get a help-MAIT/ YA! from Maria Elena Bottazzi, Baylor College of Medicine and University Of Bern!
https://science.sciencemag.org/content/371/6528/521.full
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162195235
MERCK already knows about ovalbumin virosome" :)
Development and characterization of gels and liposomes containing ovalbumin for nasal delivery
Nasal delivery is an emerging strategy to prevent both local and systemic diseases. The aim of this study was to develop a promising and innovative therapeutic system for the nasal delivery system of liposomes. Ovalbumin(OVA) was used as a model compound in this study.
https://www.sciencedirect.com/science/article/abs/pii/S1773224717305543
Search term:"ovalbumin virosome" Merck
vaccine bioprocessing handbook (1 MB)
vaccine bioprocessing handbook The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. Table of Contents 2 The SAFC ® portfolio offers customized and ready-to-use raw material solutions, backed by deep regulatory expertise. Our high-quality prod...
https://www.sigmaaldrich.com/catalog/search?term=ovalbumin+virosome&interface=All&N=0+220003049&mode=match%20partialmax&cm_re=Did%20You%20Mean-_-ovalbumin%20virosome-_-ovalbumin%20virosomes&lang=en®ion=US&focus=documents&cm_re=Did%20You%20Mean-_-ovalbumin%20virosome-_-ovalbumin%20virosomes
Table of Contents
Vaccine Process Overview. . . . . . . . . . . . . . . . 4
Viral Vaccines. . . . . . . . . . . . . . . . . . . . . . . . . 6
Spotlight: Influenza Vaccines. . . . . . . . . . . . 8
Virus-Like Particle (VLP) Vaccines. . . . . . . . . . 13
Polysaccharide Conjugated Vaccines. . . . . . . . 18
Viral Vector Vaccines. . . . . . . . . . . . . . . . . . . 20
https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma-Aldrich/Brochure/1/vaccine-handbook-process-br5237en-ms.pdf
Monophosphoryl Lipid A-Adjuvanted Virosomes with Ni-Chelating ...
onlinelibrary.wiley.com › doi › full
Dec 26, 2017 · Originally, passive encapsulation was used to generate protein- or peptide-carrying influenza virosomes. 16, 17 However, only approximately 225 ovalbumin (OVA) molecules could be encapsulated per virosomal particle using this technique. 16 In contrast, we estimate that one particle of DOGS-NTA-Ni-containing virosomes could conjugate .
https://onlinelibrary.wiley.com/doi/full/10.1002/biot.201700645
Reconstituted influenza virus envelopes (virosomes) represent efficient influenza vaccines inducing high antibody titers upon intramuscular adminsitration. Virosomes are reconstituted viral envelopes which retain the cell entry and membrane fusion characteristics of native influenza virus. Here, we show that virosomes, by virtue of their membrane fusion activity, have the capacity to deliver a virosome-encapsulated protein antigen (ovalbumin, OVA) to the cytosol of cultured murine bone-marrow-derived dendritic cells (DCs) and thus to the MHC class I presentation pathway. Accordingly, immunization of mice with OVA-containing virosomes resulted in efficient priming of an OVA-specific class I MHC-restricted cytotoxic T lymphocyte (CTL) response. These results indicate that virosomes have the capacity to prime a broad immune response, inducing not only humoral but also cellular immunity.
J Wilschut*, A Huckriede, L Bungener, T Daemen, T Stegmann, A Palache
https://research.rug.nl/en/publications/the-virosome-concept-in-influenza-vaccines